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Abstract
Endothelial Protein C Receptor (EPCR) is a Major Histocompatibility Complex homologue, with established roles down-
regulating coagulation and in endothelial protection. Expressed predominantly on endothelium, EPCR affects inflam-
matory, apoptotic and cell proliferation pathways by binding to activated protein C (APC). However, EPCR can also be
expressed on cancer cells, although the underlying reasons are unclear. Moreover, although EPCR has been linked with
chemosensitivity in lung cancer, its clinical significance in many tumours is unknown. Here, we explored its signifi-
cance in colorectal cancer (CRC). Bioinformatic methods revealed EPCR overexpression in many epithelial cancers,
which was confirmed on CRC epithelial tumour cells by immunohistochemistry. EPCR upregulation resulted from gene
amplification and DNA hypomethylation, and occurred in concert with a cohort of neighbouring genes on chromosome
20q, a region previously implicated in chemoresistance. As in endothelial cells, EPCR reproducibly mediated ERK path-
way activation in a model CRC cell line following APC treatment. However, EPCR knockdown studies failed to highlight
compelling EPCR-intrinsic impact on CRC cell phenotype, with limited effects on chemosensitivity and no effect on
invasion observed, while EPCR appeared to decrease CRC cell migration. Consistent with these observations, differential
EPCR expression did not influence response to chemotherapy in a human CRC cohort. Our results provide a compelling
explanation for how EPCR is upregulated in diverse epithelial malignancies. They indicate that the clinical significance
of EPCR varies across different tumour types. Furthermore, they raise the possibility that the prognostic significance of
EPCR in certain tumours relates significantly to co-upregulation of neighbouring genes on chromosome 20q. There-
fore, efforts to exploit EPCR as a prognostic marker should be focussed on specific tumours, and in such scenarios
EPCR-co-dysregulated genes may represent potential axes for therapeutic intervention.
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Introduction
Endothelial protein C receptor (EPCR) is a type I trans-
membrane protein largely restricted in expression to endo-
thelium. Homologous to Major Histocompatibility
Complex molecules, it has well recognised roles in damp-
ening coagulation, and in endothelial protection, which
are initiated via its interaction with activated Protein C
[1–5]. There has been increasing interest in EPCR’s
potential role and clinical significance in cancer, follow-
ing several reports indicating overexpression on epithelial
tumour cells [6,7]. However, studies in different tumour
types [8–12], largely focused on exploring EPCR-
intrinsic effects on cancer cell phenotype or tumour
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progression in murine models, have yielded conflicting
results regarding the effects of EPCR on epithelial
tumourigenesis. EPCR expression in in vitro systems and
mouse models has been proposed to increase tumour cell
proliferation/migration [2], or increases metastatic burden
[1], in gastric and lung cancer, respectively. In a murine
breast cancer model EPCR distinguished a cancer stem
cell-like populationwith a high tumour-initiating capacity,
and in vivo EPCR blockade attenuated tumour growth
[10]. Conversely, in murine models of melanoma [4], and
mesothelioma [5] EPCR expression decreased metastasis,
limiting tumour growth and burden, respectively.
Despite such conflicting results, EPCR overexpres-
sion in cancer clearly may be clinically relevant.
EPCR was found to be a marker of chemoresistance
in tumour cell lines [6], including colorectal cancer
cell lines such as HCT116. Furthermore, EPCR
expression is predictive for chemotherapy response in
early stage non-small cell lung cancer [8]. Finally, in
ovarian cancer, serum EPCR expression correlates
with the tumour marker CA-125, suggesting possible
clinical relevance as a biomarker [13].
Here we examined the overexpression of EPCR in
cancer, focusing on its role in colorectal cancer (CRC).
This stemmed from our previous work highlighting
EPCR as a direct ligand for Vd2-negative cd T cells
[14,15], which are the predominant tissue subset of
these unconventional T cells, and are thought to possess
potent anti-tumour effector capabilities. We sought to
understand the extent and significance of EPCR expres-
sion in epithelial cancers, including the cellular mecha-
nisms underlying its overexpression, its functional
significance in transformed tumour cells and its clinical
significance. Notably, EPCR-associated signalling path-
ways in endothelium have potential relevance in cancer,
overlapping with key proliferative (ERK/AKT) and
apoptotic pathways (BAX, BCL2), and raising the pos-
sibility that dysregulated ECPR expression on trans-
formed epithelial tissue may directly effect similar
mechanisms to promote tumour cell survival and
growth. The role of EPCR in CRC, a tumour type with
high mortality and prevalence, has not been explored,
and in view of the well-established developmental path-
way and pathological characterisation in this setting,
CRC was selected as a promising human model in
which to clarify the role of EPCR in tumourigenesis.
Methods
TCGA bioinformatic analysis
Oncomine (Compendia Bioscience, Thermo Fisher
Scientific, Waltham, Massaschusetts, USA) was used
for analysis and visualisation of EPCR expression in
multiple tumour types [16]. EPCR mutation, methyla-
tion, copy number, expression data, and pathological
and clinical data were extracted from The Cancer
Genome Atlas (TCGA) project via the cBioportal
tool [17–20]. Cancer cell line encyclopaedia (CCLE)
[21] data were extracted from the CCLE portal and
cBioportal. Data were tabulated and analysed with
The Integrative Genomics Viewer [22] and Excel
(Microsoft Corp., Redmond, Washington, USA).
Pearson correlations were performed for parametric
data, and Spearman correlations for nonparametric
data. Significance tests were performed in Minitab
(Minitab Inc., State College, Pennsylvania, USA)
using T-tests for parametric data and Mann-Whitney
U for nonparametric data. Normality of distributions
were confirmed using the Anderson–Darling Test.
Sample collection
Patient tumour specimens used to confirm EPCR expres-
sion were collected from the University of Birmingham
Human Biomaterials Resource Centre (HBRC) (approval
number: 11-058). Survival analysis used tumour samples
from the MRC COIN study (ISRCTN27286448), under
ethical approval 13/WM/0339 [23]. All patients had pro-
vided informed consent for tissue usage.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as pre-
viously reported [24] (supplementary materials and
methods). IHC slides were imaged as whole slides on
a Vectra 2.0 (Perkin Elmer) imaging system. Subse-
quent imaging analysis used inForm software (Perkin
Elmer, Waltham, Massaschusetts, USA), and
involved development of trained tissue and cell seg-
mentation algorithms validated by a consultant
pathologist (PT). Immunoreactivity intensities were
determined on a per cell basis, and H scores (the
product of reactivity intensity [0–3] and percentage
coverage [0–100] giving a score from 0–300) were
created by the inForm software. Tumour region and
Stroma region H scores across all slides were col-
lated and compared using the unpaired T-test.
COIN study slides were stained for EPCR at the Uni-
versity of Birmingham’s HBRC biobank using a Bond-
max Autostainer (Leica Biosystems, Wetzlar, Germany).
Anti-EPCR primary antibody (R&D Systems, Minneap-
olis, Minnesota, USA, clone 304519) was incubated for
10 minutes (dilution of 1:200) with antigen retrieval at
pH 9. Whole slides were scanned using a Leica SCN400
(Leica Biosystems, Wetzlar, Germany) slide scanner.
Scanned slides were analysed using Definiens Tissue
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Studio software (Definiens AG, Munich, Germany).
Tumour regions of each slide weremanually identified, and
trained segmentation algorithms used to separate epithe-
lium and stromal regions. EPCR immunoreactivity was
then analysed on a regional basis, by automated quantita-
tion of the percentage of pixels within tense, moderate,
weak or no staining in each area, and used to create a per-
cental score for each region. Hypermutation status data
were available for tumour samples from theCOIN samples,
allowing comparison with staining results. The majority of
the samples analysed were microsatellite stable (MSS)
(103/153), whereas the remainder either did not have data
or failed microsatellite testing. No statistically significant
correlationwith EPCR staining level was observed.
Clinico-pathological data for both the local and
COIN trial cohort of CRC cases are presented in sup-
plementary material, Tables S1 and S2, respectively.
shRNA transfection
Five EPCR shRNA clones and one control shRNA len-
tiviral particles were obtained from Sigma-Aldrich (St
Louis, Missouri, USA) (supplementary materials and
methods). HCT116 cells or HT29 cells were grown to
70–80% confluence in Dulbecco’s Modified Eagle
Medium (DMEM) with Fetal Calf Serum (FCS).
shRNA lentiviral particles were added at multiplicity
of infection (MOI) of 5, 1.5 and 0.5. shRNA transduc-
tants were selected for Puromycin (Sigma-Aldrich, St
Louis, Missouri, USA) resistance. EPCR-overexpressing
HT29 cells were a kind gift from Julie Dechanet-
Merville (University of Bordeaux, France).
Activated protein C ERK phosphorylation
Activated Protein C (APC, Sigma-Aldrich, St Louis,
Missouri, USA) was added to confluent HCT116 cells
after 48 h of serum starvation. APC was added in the
presence or absence of EPCR function blocking anti-
bodies after which cells were lysed. Cell lysates were
separated by gel electrophoresis, transferred to PVDF,
and probed with anti-ERK/pERK primary antibodies
(New England Biolabs, Ipswich, Massachusetts, USA,
4370S &4695S) and goat anti-rabbit HRP conjugated
secondary antibodies, prior to development using ECL.
Microarray
HCT116 cells were treated with APC after serum starva-
tion (supplementary materials and methods). RNA was
extracted from cells using the RNeasy Plus Kit (Qiagen,
Hilden, Germany) alongside negative controls. Two-
colour Agilent Microarray was carried out at the Func-
tional Genomics Facility (University of Birmingham);
three experimental replicates and a minimum of two
technical replicates were performed for each specimen.
APC treated cells were assigned to Cy5 and controls to
Cy3. Differential gene expression data were produced in
R using the Limma package (Bioconductor) after ‘Loess’
normalisation [25–27]. Genes with a Bayes factor >5 or
an adjusted P value < 0.05 (Benjamini and Hochberg’s
method) were considered for further analysis, which was
performed using DAVID [28,29] and GSEA [30,31].
MTT, BrdU, and migration assays
Established protocols were used to carry out 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) metabolic activity assays and bromodeoxyuri-
dine (BrdU) cell proliferation assays [following manu-
facturer’s instructions, Roche, (Roche Applied Science,
Penzberg, Germany)] as previously described [32] and
migration assays in wild type and EPCR knockdown
cells (see supplementary materials and methods).
Survival analysis
Clinical data for patients in the COIN study were
obtained from the MRC Clinical Trials Unit (supple-
mentary materials and methods). The median EPCR
percentage score was used to divide patients into
EPCR high and low categories. Additionally, a sepa-
rate analysis with COIN data was carried out to com-
pare the top 20% of EPCR expressors against the
bottom 20%. Statistical modelling was performed
using Stata 12.1 (Stata Corp, College Station, Texas,
USA). Both prognostic and predictive analyses utilized
the Cox proportional hazards model, and adjusted for
factors that significantly associated with progression
free survival (PFS) to p <0.05. Given that baseline 1-
year survival was 24%, if the comparator group had a
higher response than this, 153 samples had 80% power
to detect an increase in 1-year survival from 24 to 45%
(HR5 0.56), and 70% power to detect an increase to
42% (HR5 0.61). If the comparator group had a lower
response, 153 samples had 80% power to detect a
decrease in 1-year survival from 24 to 9.5%
(HR5 1.66), and 70% power to detect a decrease to
11% (HR5 1.57). The top/bottom 20% of EPCR
expressors were separately compared, with cut offs for
EPCR expression based on median expression of
EPCR, thereby dividing patients into two equal groups.
No significant differences were observed.
Results
EPCR is overexpressed in multiple tumour types
The Oncomine database was interrogated to compare
EPCR mRNA expression in multiple tumour types
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relative to normal tissue. EPCR was upregulated in
tumour versus normal in 126 separate datasets and
downregulated in 50 datasets, which included 21 dif-
ferent cancer types. Of all cancer types, CRC had the
highest level of EPCR overexpression, and the most
datasets in total in which EPCR was overexpressed
(Table 1). In CRC, across nine separate nonoverlap-
ping datasets, EPCR was strikingly overexpressed
(p< 0.0001). This suggested that amongst all
tumours, CRC had one of the highest and most con-
sistent levels of EPCR mRNA upregulation.
EPCR is expressed in colorectal cancer
To confirm upregulation in CRC at a protein level,
EPCR expression was assessed in whole sections from
30 colorectal cancers and adjacent normal regions
using immunohistochemistry (IHC). Before this, EPCR
immunoreactivity was validated by EPCR knockdown
in HCT116 cells, with staining of endothelial vessels a
further positive control in normal/tumour sections (sup-
plementary material, Figure S1). Overall, the majority
of immunoreactivity was observed in tumour epithelial
tissue. Sections were imaged on the Vectra platform
and EPCR immunoreactivity assessed using inForm
software (Figure 1). This confirmed that EPCR expres-
sion was higher in tumour regions compared to normal
regions (p< 0.0001, mean H scores 244.2 and 87.6,
respectively). In addition, samples from the COIN clin-
ical trial were used to independently confirm EPCR
expression in CRC (n5 153). Immunoreactivity was
assessed using Definiens Tissue Studio, allowing inde-
pendent confirmation of EPCR expression in terms of
both the cohort examined and the digital pathology
scoring package used. Positive EPCR staining was
observed in all cases. In epithelium, the mean H score
was 216.1 (range 155.2 – 296.0). In stroma, the mean
H score was 211.5 (range 180.7 – 261.4).
Finally, immunoreactivity to what appeared to be
mast cells was observed consistently across all tissue
sections, and confirmed by flow cytometry and
immunoreactivity to individual cells with both
EPCR-specific mAb and mast cell marker mAbs in
serial sections (supplementary material, Figure S2).
This is the first report of immunoreactivity to EPCR
on mast cells to our knowledge.
EPCR overexpression in CRC is mediated by gene
amplification and hypomethylation
To determine possible mechanisms underpinning
EPCR overexpression, we analysed public bioinfor-
matic genomic and transcriptomic datasets [19]. The
EPCR gene (PROCR), though rarely mutated in any
cancer type, was frequently amplified (Figure 2A). In
the CRC TCGA dataset, 73.8% of tumours had either
low level gain or high level amplification of the
PROCR gene [GISTIC (Genomic Identification of
Significant Targets in Cancer) score of 1 (low level
amplification) or 2 (high level amplification)]. In
CRC, gene amplification was significantly associated
with increased mRNA expression (p <0.05). Overall,
there was a strong correlation between PROCR copy
number and mRNA expression (Figure 2B), (Spear-
man rho5 0.325, p< 0.0001). Of the top 10% of
EPCR expressors, 90% had either low level gain
(GISTIC score 1) or high level amplification (GIS-
TIC score 2) of the PROCR gene. Moreover, of the
top 10%, two cancers were GISTIC 0 whereas seven
were GISTIC 2; conversely, of the bottom 10%,
seven were GISTIC 0 whereas two were GISTIC 2
(p5 0.06). Using the same dataset, chromosomally
unstable (CIN) cancers had significantly higher
EPCR expression than the non-CIN group (z-scores
of 0.448 and 0.030, respectively, p< 0.01). Despite
this, some EPCR over expressors were of the non-
CIN microsatellite unstable (MSI) hypermutated
Table 1. ONCOMINE expression data – number of datasets in
which EPCR is significantly differentially expressed in cancer
versus normal to p < 0.0001. Cell colour is determined by the
highest overexpression (left column) or under expression (right
column) gene rank percentile for EPCR
Analysis type by cancer Cancer versus normal
Bladder cancer 4
Brain and CNS cancer 13
Breast cancer 3 9
Cervical cancer 3
Colorectal cancer 22
Oesophageal cancer 8 2
Gastric cancer 8
Head and Neck cancer 14
Kidney cancer 9 1
Leukaemia 8 1
Liver cancer 4 2
Lung cancer 5
Lymphoma 11 1
Melanoma 2
Myeloma 1
Other cancer 12 4
Ovarian cancer 10
Pancreatic cancer 5
Prostate cancer 9
Sarcoma 2 4
Percentile of under expressed
genes containing EPCR
Percentile of overexpressed genes
containing EPCR
1% 5% 10% 10% 5% 1%
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Figure 1. Digital software analysis of EPCR-stained CRC sections confirms that EPCR is overexpressed on tumour compared to normal
epithelium. (A) Whole slide scanned image of CRC region surrounded by normal colonic mucosa. (B) 5x magnified image of tumour
with adjacent normal colonic mucosa. (C) 203 magnified image of tumour region, demonstrating strong EPCR staining. (D) 203
magnified image of normal region, with negative staining of colonic crypts. (E) Area for digital analysis with inForm software. (F)
Image (E) with inForm tissue-segmentation through automated algorithm. Red5 epithelium, green5 stroma, yellow5 background.
(G) Image (F) with staining intensity within tumour cells. Red5 strong, orange5moderate, yellow5weak.
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subtype. These tumours were mostly diploid; thus,
gene amplification could not account for overexpres-
sion. We therefore suspected that epigenetic factors
might also influence EPCR expression. Indeed, there
was a strong inverse correlation between PROCR
promoter methylation and gene expression across the
Figure 2. Legend on next page.
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entire patient dataset (Spearman rho 20.59,
p< 0.001). Overall, 92.8% of CRCs were hypome-
thylated at the PROCR promoter (HM27< 0.2). Of
the top 10% of EPCR expressors (N5 20), all were
hypomethylated at this promoter (b-value< 0.2),
whereas of the bottom 10% (N5 20), five were
hypermethylated (b-value< 0.2; p5 0.047). When
copy number data were combined with methylation
data, it became clear that hypomethylation played a
key role in determining expression across all patient
groups (Figure 2C,D). Tumours overexpressing
EPCR had significantly lower methylation than those
that did not (p< 0.001). Amplification and
hypomethylation when combined associated with the
highest expression (Figure 2E).
EPCR expression is associated with chromosome
20q amplification
To determine whether PROCR was co-expressed with
other genes, we explored TCGA expression and
genetic data. Most genes whose expression correlated
most closely with PROCR were located in the same
chromosomal region as PROCR – chromosome 20q
(Table 2). On an individual patient basis, PROCR
gene amplification was frequently associated with
amplification of all genes on chromosome 20q
(Figure 3A). Across the entire 195 patient cohort, the
copy numbers of most (99.42%) chromosome 20q
genes correlated positively with PROCR copy num-
ber (Figure 3B), whereas a significantly smaller pro-
portion of 20p genes were correlated (36.90%,
p< 0.05 [chi-squared]). Also, 55.33% of chromosome
20q genes correlated with PROCR in terms of pro-
moter methylation. However, a similar proportion of
chromosome 20p genes were also correlated in terms
of methylation (51.30%, p5 0.47, chi-squared;
Figure 3C). Finally, the expression of a high propor-
tion (53.80%) of chromosome 20q genes correlated
positively with PROCR expression, although the cor-
relations were not as large in magnitude as those
seen with copy number (Figure 3D). A significantly
smaller proportion of chromosome 20p genes were
correlated in terms of expression (13.72%, p< 0.05
[chi-squared]). This suggests that whilst PROCR
copy number and expression co-regulation are a chro-
mosome 20q regional phenomenon, regulation of
methylation is less region specific.
Across the entire colon cancer dataset, chromo-
some 20q was amongst the most frequently amplified
chromosomal regions (Figure 3E). Additionally, chro-
mosome 20q was amplified across a range of cancer
types, including several in which EPCR has been
shown to be expressed, including melanoma [11],
gastric cancer [9] and lung squamous cell cancer [8]
(Figure 3E). These data suggest that EPCR may be a
Figure 2. EPCR expression is associated with PROCR gene amplification and hypomethylation. (A) The EPCR gene (PROCR) is fre-
quently amplified but rarely deleted or mutated across a range of cancer types and databases [17,20]. (B) In colon cancer, increases
in PROCR copy number are associated with higher mRNA expression (p <0.01). (C) Copy number and methylation both impact upon
EPCR expression. This graph includes 195 colorectal cancer patients from the TCGA dataset. The highest EPCR expression is in
patients with amplification of PROCR in association with low methylation. Lower expression is commonly associated with higher
methylation and diploid copy numbers or low level gain. (D) Heatmap showing correlation between PROCR mRNA expression, pro-
moter methylation and copy number values (blue5 low, red5high). EPCR correlates positively with amplification and negatively with
methylation. (E) Relationship between PROCR methylation, GISTIC copy number scores and expression. The upper box highlights the
group with low methylation and highest expression. These patients tend to have low level gain or high level amplification. The lower
box highlights most highly methylated patients, who have low expression regardless of copy number status.
Table 2. Genes most highly co-expressed with EPCR in TCGA
CRC dataset, and their chromosomal locations
Gene Symbol
Spearman Score
versus PROCR
Chromosomal
location
HM13 0.45 20q11.21
PDRG1 0.44 20q11.21
C20ORF24 0.43 20q11.23
PSMA7 0.43 20q13.33
TPD52L2 0.43 20q13.33
TRPC4AP 0.43 20q11.22
MRGBP 0.43 20q13.33
ADRM1 0.42 20q13.33
BRI3 0.42 7q21
EIF6 0.41 20q11.22
ATP6V1F 0.41 7q32.1
EFNA2 0.41 19p13.3
SSUH2 0.41 3p25.3
NDRG3 0.4 20q11.23
RHOD 0.4 11q13.2
EDEM2 0.39 20q11.22
ACTR5 0.39 20q11.23
DYNLRB1 0.39 20q11.22
CEBPA 0.39 19q13.11
FAM96B 0.39 16q22.1
UQCC1 0.38 20q11.22
PIGU 0.38 20q11.22
ROMO1 0.38 20q11.22
AHCY 0.38 20q11.22
NEU1 0.38 6p21.33
TOMM34 0.38 20q13.12
TCFL5 0.38 20q13.33
RPS21 0.38 20q13.33
TLDC2 0.37 20q11.23
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marker of tumours with chromosome 20q amplifica-
tion, which has been linked with poor outcome
[33,34].
Carvalho et al [34] previously identified three
regions of chromosome 20q commonly amplified in
CRC [34]. PROCR is located within the first of these
Figure 3. Legend on next page.
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(SRO1), which spans 32–36 Mb. The group identi-
fied seven putative oncogenes based on upregulation
in carcinomas versus adenomas, association with
chromosome 20q amplification, and correlation
between copy number and gene expression. Of these
seven genes, six correlated significantly with EPCR
expression (Table 3). Furthermore, EPCR expression
was correlated significantly with 13/13 ‘cancer initiat-
ing genes’ located on chromosome 20q identified by
Tabach et al [33]. Finally, PROCR correlated signifi-
cantly with a gene ranked first in a microarray-based
CIN signature (TPX2) [35], reinforcing the view that
its expression is associated with chromosomal
instability.
Having established that EPCR upregulation denotes
regional dysregulation, we then sought to test the sig-
nificance of upregulated EPCR expression on CRC
tissue.
EPCR is expressed on multiple CRC cell lines
First, we investigated EPCR expression in CRC cell
lines. Using the Cancer Cell Line Encyclopaedia
[21], we selected five lines with high EPCR mRNA
expression (HCT116, HT29, RKO, COLO320 and
SW480), and confirmed EPCR protein expression
with flow cytometry (supplementary material, Figure
S3A–E). Both HCT116 and HT29 had high expres-
sion, and these were selected for further in vitro stud-
ies as they represent the two main biological
subtypes of CRC (MSI-H and CIN respectively).
EPCR expression was also investigated in the non-
tumourigenic AA/C1 adenoma cell line [36]. AA/C1
expressed low levels of EPCR. However, a tumouri-
genic derivative (AA/C1 10C) had increased EPCR
expression (supplementary material, Figure S3F,G).
Exogenous activated protein C (APC) induces
EPCR-dependent ERK phosphorylation in CRC lines
APC treatment of vascular endothelial cells has been
shown to induce EPCR-dependent activation of ERK
pathways, which are implicated in epithelial transfor-
mation [37]. To establish a proof of principle that
exogenous APC could also induce ERK phosphoryla-
tion in a model CRC cell line, we treated serum-
starved HCT116 cells with APC for 5 min. This led
to an increase in ERK phosphorylation (Figure 4A),
which was inhibited by EPCR-blocking antibodies
(Figure 4B), confirming that such APC-induced ERK
phosphorylation was EPCR dependent. In addition, to
determine if CRC cells were capable of producing
endogenous Protein C (PC), serum-starved HCT116
cells were lysed and western blots performed for PC
(supplementary material, Figure S4A). PC was
detected in the cell lysate, and protease-activated
receptor 1 (PAR1) staining was observed alongside
EPCR in sections from identical blocks (supplemen-
tary material, Figure S4B,C). These results establish
that EPCR can in principle activate ERK signalling
when expressed on CRC cells in response to APC,
and that components of the APC pathway can be
expressed in CRC in vivo.
Figure 3. EPCR expression is associated with chromosome 20q amplification. (A) Copy numbers of chromosome 20 genes in 195
TCGA colorectal cancer patients. Genes are organised by chromosomal location (20p is left, 20q is right). Blue represents loss of
gene, red represents gain of gene and white represents no change in copy number. The chromosome 20q region is commonly ampli-
fied in CRC [22]. The location of PROCR is indicated by the arrow. (B-D) Pearson correlations for PROCR gene copy number (B), meth-
ylation (C), and expression (D) with genes on chromosome 20, arranged by chromosome region. PROCR is located on 20q11.2. Red
lines represent the thresholds of statistical significance (Pearson value> 0.1405 or <20.1405, significant to p <0.05). (E) Chromo-
some 20q is one of the most frequently amplified regions in colon cancer and across a range of cancer types (colon adenocarcinoma,
breast adenocarcinoma, lung squamous cell cancer, gastric adenocarcinoma and melanoma TCGA data). Chromosomes are ordered
from 1 to 23, X, Y. Images (A) and (E) were created using Integrated Genomics Viewer and Cbioportal.
Table 3. Correlation of Carvalho et al’s putative oncogenes [34] located on chromosome 20q versus PROCR. Correlation values show
Pearson scores (R) versus PROCR in the TCGA CRC dataset. p< 0.05 where R> 0.1405, highlighted red
Chromosomal location Copy number Methylation Expression
C20orf24 20q11.22 0.989164 0.227405 0.498511
AURKA 20q13.2 0.907967 0.009653 0.239549
RBM38 (RNPC1) 20q13.32 0.928319 0.21619 0.053815
NELFCD (TH1L) 20q13 0.901242 0.155924 0.334379
ADRM1 20q13.33 0.920162 0.295276 0.454516
MRGBP (C20orf20) 20q13.33 0.909783 N/A 0.409151
TCFL5 20q13.3-qter 0.909783 0.214221 0.364161
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APC treatment affects gene transcription in
HCT116 cells
Having established that APC can induce ERK phospho-
rylation in HCT116 cells, the effect of APC treatment on
gene transcription was then assessed. APC treatment of
serum-starved HCT116 cells and subsequent microarray
analysis identified a set of differentially expressed genes
(Bayes factor> 5) (supplementary material, Table S3).
Gene set enrichment analysis (GSEA) (Table 4 and
supplementary material, Figure S5) revealed that a
large proportion of genes were ribosomal and/or
associated with gene transcription; and also, that sev-
eral gene sets associated with epidermal growth fac-
tor (EGF) signalling were enriched (supplementary
material, Figure S5A–C), consistent with ERK path-
way stimulation. Finally, a gene set containing genes
upregulated by thrombin signalling in HUVEC cells
was enriched, consistent with thrombin and APC’s
common signalling pathways (supplementary mate-
rial, Figure S5D).
EPCR knockdown increases chemoresistance and
migration in HCT116 cells
Having established that EPCR signalling can induce
ERK phosphorylation and alter gene transcription, we
aimed to determine whether EPCR overexpression
provided any functional benefit to tumour cells. Pre-
vious work has demonstrated that EPCR is a marker
of chemoresistant cell lines, including HCT116 [6].
To further examine the effect of EPCR expression on
chemosensitivity, we knocked down EPCR expres-
sion in HCT116 cells using two shRNA constructs,
which induced high (clone 969 – 90%) and medium
(clone 379 – 60%) levels of knockdown. EPCR
knockdown significantly reduced the toxicity of 5FU
and epirubicin in MTT and BrdU assays of cellular
viability and proliferation (Figure 5A–D), suggesting
EPCR increased chemosensitivity in this setting.
Transwell assays were performed to determine
how EPCR expression affected cellular migration.
Over 48 hours, HCT116 cells with high EPCR
knockdown had a significantly higher rate of migra-
tion than control cells (p< 0.001) or medium-level
EPCR knockdown cells (p< 0.001) (Figure 5E).
However, no significant differences between the
groups were observed in invasion assays.
To determine whether the effect of EPCR perturba-
tion was similar in a MSS/CIN cell line, we repeated
experiments in HT29 cells. In HT29 cells, EPCR
knockdown did not consistently affect MTT and BrdU
chemosensitivity assays. However, as with HCT116
cells, high EPCR knockdown (>95%) increased cellu-
lar migration in the Transwell assay (p< 0.01). No dif-
ference was observed with knockdown in QCM
invasion assays. HT29 EPCR overexpression (to over
sixfold above wild type HT29) did not consistently
affect chemosensitivity, migration, or invasion.
EPCR expression is not predictive for
chemotherapy or cetuximab responsiveness in
CRC
Previous studies have indicated that EPCR is a marker
for chemoresistant cell lines [6], and conversely its
expression may predict chemotherapy responses in
early stage lung cancer [8]. Furthermore, we have
shown that EPCR perturbation can marginally affect
CRC cell line chemosensitivity. We wanted to deter-
mine whether EPCR could affect chemosensivity in
vivo. In addition, having established that EPCR can
mediate APC-dependent ERK phosphorylation on CRC
cells, we were also interested in the potential impact of
EPCR upregulation on clinical responses to EGFR
monoclonal antibodies (mAb) in CRC patients. Patients
Figure 4. APC induces ERK phosphorylation, which is inhibited
by EPCR-blockade. (A) Western blotting for pERK and Total-ERK
of lysates from serum-starved HCT116 cells that had been
treated with APC for 5 min. Negative controls were serum
starved only. Positive controls were treated with 50% FCS for
10 min. (B) Western blotting after pre-treatment with EPCR-
blocking antibody.
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with KRAS mutation do not respond to EGFR mAbs
due to ‘bypass signalling’ resulting from constitutively
active MEK/ERK signalling. As EPCR-mediated sig-
nalling induces ERK phosphorylation, we hypothesised
that EPCR could also act as a bypass signalling path-
way in an analogous manner.
To determine whether differential EPCR expres-
sion is associated with altered chemotherapy or
EGFR monoclonal antibody (cetuximab) responsive-
ness in CRC patients, immunohistochemistry for
EPCR was performed on 153 CRC tumour samples
from the MRC COIN study [23] and analysed using
Definiens Tissue Studio software (see supplementary
materials and methods). Of these, 71 were from the
chemotherapy arm, and 82 were from the chemother-
apy plus cetuximab arm. Survival analyses indicated
no significant difference in PFS between EPCR high
and low cases (divided by median EPCR expression)
across all patients, irrespective of whether it was
assessed on tumour epithelium or stroma (Figure 6,
p5 0.367 and 0.568, respectively), when both treat-
ment arms were analysed individually, or when com-
paring the top and bottom 20% of EPCR expressors.
Finally, EPCR did not predict for survival in either
treatment arm after exclusion of KRAS mutant cases.
These data suggest that, given the power of the anal-
ysis (see Methods section), the extent of EPCR
expression does not predict for chemotherapy or
cetuximab responsiveness in CRC.
Discussion
EPCR, a receptor with antiapoptotic and proliferative
effects [3–5], is known to be expressed on various
Table 4. Top 30 gene sets in gene set enrichment analysis of APC-treated HCT116 cells versus control cells
Name of gene set Size (Genes) Enrichment score FDR q value FWER P value Rank at max
REACTOME_PEPTIDE_CHAIN_ELONGATION 83 0.830811 0 0 958
REACTOME_INFLUENZA_VIRAL_RNA_
TRANSCRIPTION_AND_REPLICATION
97 0.791672 0 0 958
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_
PROTEIN_TARGETING_TO_MEMBRANE
106 0.767984 0 0 958
KEGG_RIBOSOME 85 0.838541 0 0 958
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_
REGULATION
91 0.791225 0 0 958
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED
_BY_THE_EXON_JUNCTION_COMPLEX
102 0.748643 0 0 958
REACTOME_TRANSLATION 131 0.695274 0 0 958
REACTOME_INFLUENZA_LIFE_CYCLE 130 0.687707 0 0 958
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES 61 0.72625 0 0 958
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX
_AND_SUBSEQUENTLY_THE_43S_COMPLEX
35 0.815359 0 0 958
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING
_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_
AND_SUBSEQUENT_BINDING_TO_43S
43 0.737235 0 0 958
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 44 0.714276 0 0 958
REACTOME_METABOLISM_OF_MRNA 202 0.517838 0 0 958
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP 50 0.642381 0 0 1173
NAGASHIMA_EGF_SIGNALING_UP 52 0.629965 0 0 2671
PECE_MAMMARY_STEM_CELL_DN 128 0.529283 0 0 1489
REACTOME_METABOLISM_OF_RNA 245 0.453754 0 0 958
NAGASHIMA_NRG1_SIGNALING_UP 160 0.485804 7.41E-05 0.001 2099
CHASSOT_SKIN_WOUND 10 0.878359 2.08E-04 0.003 1642
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_
TRANSITION_DN
63 0.526858 3.91E-04 0.006 886
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP 22 0.674004 3.73E-04 0.006 551
REACTOME_OLFACTORY_SIGNALING_PATHWAY 102 0.474621 5.87E-04 0.01 3844
REACTOME_METABOLISM_OF_PROTEINS 382 0.395476 8.40E-04 0.015 2516
UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN 34 0.597898 8.05E-04 0.015 4451
TIEN_INTESTINE_PROBIOTICS_6HR_UP 50 0.533304 0.00148 0.028 1092
HSIAO_HOUSEKEEPING_GENES 363 0.389684 0.00247 0.049 1536
LEE_LIVER_CANCER_HEPATOBLAST 15 0.701492 0.00248 0.051 3202
AMIT_EGF_RESPONSE_40_HELA 39 0.545263 0.00395 0.083 2970
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 46 0.535978 0.00390 0.085 1692
BILANGES_SERUM_RESPONSE_TRANSLATION 33 0.579625 0.00436 0.099 1489
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cancer cell lines [6,38]. However, its expression in
CRC has not previously been addressed. Using robust
digital immunohistochemistry algorithms and bioin-
formatic analyses we have demonstrated that EPCR
is aberrantly expressed in CRC tissue, with expres-
sion increased in cancer compared to normal mucosa
in all cases tested. Of note, the use of a robust
quantitative, pathologist-informed digital pathology
algorithm (via the InForm software package) that
was specifically educated to analyse colonic tissue
enabled statistically significant EPCR upregulation to
be detected in a relatively small sample set (30 in-
house samples). Confirmation of this upregulation via
a comparable but independent approach and
Figure 5. In HCT116 cells, EPCR knockdown with shRNA decreases chemosensitivity and increases migration. (A) Flow cytometry data
confirming knockdown of EPCR expression with shRNA (vector 969) compared to control cells. (B) EPCR expression in wild-type cells
and shRNA transfected cells (vectors 969 and 379), as a percentage of control vector-transfected cells. (C) MTT scores for control
and shRNA knockdown (clone 969) HCT116 and HT29 cells after treatment with 5FU (32 lM), shown as a percentage of control cells.
(D) BrdU scores for control and shRNA knockdown (clone 969) HCT116 and HT29 cells after treatment with 5FU (32 lM), shown as a
percentage of control cells. (E) 48 h Transwell migration assay – number of cells that migrated through Transwell membrane for each
clone in five counted regions. (F) 48 h QCM invasion assay. In panels (C-F), asterisks represent statistical significance of EPCR-low
cells versus control cells (*p< 0.05, **p <0.01, ***p <0.001). Bars represent standard error.
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algorithm using the Definiens Tissue Studio package,
and applied to a separate sample set, provided power-
ful corroboration that EPCR is indeed aberrantly
upregulated at the protein level in CRC.
In addition, although EPCR expression has been
investigated in various epithelial cancers, the mech-
anisms underlying its upregulation have remained
unclear. Importantly, our study shines light on these.
We show that EPCR upregulation results from both
chromosome 20q amplification and promoter hypo-
methylation, processes likely relevant to multiple
tumour types. Specifically, chromosome 20q ampli-
fication occurs as a result of chromosomal instabil-
ity (due to loss of the CIN suppressor genes of
chromosome 18q [39]) and occurs in many cancer
types [33,34,40–42]. Of relevance, previous studies
have confirmed EPCR expression in breast cancer,
lung cancer and melanoma, but these studies have
not related EPCR expression to chromosomal
amplification or hypomethylation [8,10,11]. Signifi-
cantly, all these tumour types are associated with
chromosome 20q amplification.
We then investigated the implications of aberrant
EPCR expression on CRC cell functional phenotype,
following studies highlighting EPCR effects on can-
cer cell migration, invasion and proliferation in dif-
ferent tumour settings [8,11,12,38]. While our results
establish the proof of principle that EPCR, via APC
binding, can stimulate ERK signalling and elicit
changes in gene transcription (as in endothelial cells),
a number of limitations are worth considering. First,
an important caveat is that these analyses were car-
ried out on a single cancer cell line (HCT116);
clearly future studies could address how the effects
of APC compared in different cellular contexts. Sec-
ond, how these effects might be modulated by the
genetics of in vivo tumourigenesis is unclear, as is
whether APC can be produced in sufficient quantities
to elicit the EPCR-mediated effects we observed.
Finally, how the diverse spectrum of tumour micro-
environmental factors might influence such effects is
unclear. Nevertheless, this in vitro result at least
establishes that, in principle, APC exposure to
EPCR-overexpressing cancer cells has the potential
to influence cancer cell signalling and transcription.
Despite these findings, our in vitro data failed to
identify compelling evidence that overexpression of
EPCR per se might provide functional advantages for
CRC cells. Interestingly, in both HCT116 and HT29
cells, EPCR expression appeared to decrease migra-
tion in in vitro assays. Furthermore, EPCR had vari-
able effects on cancer cell phenotype across cell
lines:specifically, it increased the chemosensitivity of
HCT116, consistent with a report that higher EPCR
expression was associated with superior chemother-
apy response in early stage lung cancer [8]. In con-
trast, no chemosensitivity effects were observed in
HT29 cells, and no effects on invasion were observed
in either cell line. However, an important limitation
of these experiments, and of approaches highlighting
both beneficial and detrimental effects of EPCR per-
turbation in animal models [8,9,11,12], is that they
primarily address EPCR-intrinsic effects on cancer
development, and typically focus on a small number
of cell lines. Our findings underline that the effects
of EPCR upregulation on cancer cells may be heavily
dependent on biological context, including the exact
cancer cell line (even within a single cancer cell
type) and potentially upregulation of functionally
important neighbouring genes co-amplified on chro-
mosome 20q. Indeed, while the reasons underlying
aberrant EPCR expression on the different cancer
cell lines we studied was not explored (eg
Figure 6. Kaplan-Meier curves for progression free survival in
EPCR high and low patients, divided by median EPCR expression
in Tumour epithelium (A) and Tumour stroma (B). The blue lines
represent low EPCR expression, and the red lines represent high
EPCR expression. This cohort contains 153 patients from the
MRC COIN trial.
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chromosome 20q amplification versus promoter
hypomethylation), it might conceivably affect the
nature of any co-expressed genes, and contribute to
the diverse results observed. This is a potential focus
for future studies. This perspective demonstrates the
need for models that represent the variety of biologi-
cal variants observed in the clinical scenario.
Our data establish that EPCR expression should be
interpreted in the context of chromosome 20q ampli-
fication, which is itself associated with an aggressive
and invasive phenotype, tumour progression and
metastasis formation [8,33,34,38], and is suggested to
play a causative rather than a bystander role in
tumour progression [33]. Despite this and previous
reports highlighting links between EPCR and chemo-
resistance/chemosensitivity [6,8], analysis of samples
from the MRC COIN study did not reveal any associ-
ation between EPCR expression and PFS in advanced
CRC patients treated with chemotherapy, indicating
that the impact of the EPCR-high phenotype was
insufficient to predict chemosensitivity in this setting,
although we cannot exclude the possibility of rela-
tively subtle effects beyond the power of our analy-
sis. Also, as EPCR mediates ERK phosphorylation in
CRC cells, we hypothesised it could act as a bypass
pathway during EGFR inhibition with cetuximab,
similar to KRAS mutation [23], and might represent
an additional negative predictive biomarker of cetuxi-
mab response. However, survival analysis of EPCR-
stained specimens from the COIN trial also failed to
show any association with PFS in the cetuximab
treatment arm, although formally we cannot exclude
the possibility of smaller effects, beyond the power
of our analysis to detect.
These negative results may reflect that EPCR upreg-
ulation occurs too early in tumourigenesis to be a use-
ful discriminator of clinical outcome following
diagnosis of late stage CRC. Consistent with this, chro-
mosome 20q amplification is absent in normal colonic
mucosa, but increases as disease advances from non-
progressed adenomas to progressed adenomas, and is
found in most metastatic samples [34,40,43]. This is
consistent with our findings that AA/C1 10C, a malig-
nant variant of the AA/C1 adenoma cell line, had
increased EPCR expression [36], and our observation
that all CRC samples expressed EPCR to some extent.
Also, our analyses highlighted that PROCR expression
correlated strongly with 6/7 putative oncogenes and 13/
13 ‘cancer initiating genes’, all located alongside it on
chromosome 20q [33,34]. In CRC, aberrant EPCR
expression may therefore result from chromosome 20q
amplification occurring early in transformation, which
is suggested to promote cancer initiation independently
of other chromosomal abnormalities [33]. In contrast,
the finding that high EPCR expression predicts for pos-
itive chemotherapeutic response in lung cancer [8] sug-
gests that it may represent a clinically useful biomarker
in some settings. Although this could reflect EPCR-
intrinsic effects on cancer cell phenotype, the effect of
regionally co-expressed genes could alternatively
explain the EPCR-high phenotype, and EPCR may rep-
resent a clinically useful surrogate marker of chromo-
some 20q amplification in this setting. This possibility
justifies further investigation, but could imply an
impact of chromosome 20q genes on chemosensitivity.
Owing to its relevance in dampening coagulation, eval-
uation of EPCR as a biomarker of thrombotic risk in
cancer is also of interest.
Previously we highlighted EPCR as a ligand for
human cd T-cell receptors (TCRs), mediating recog-
nition of CMV-infected endothelial cells by Vd2-
negative T cells [15]. This study suggests that EPCR
in principle could act as stress ligand for cd T cells
in cancer, as it will be consistently upregulated in
multiple transformed tissues, including in early stages
of tumourigenesis. Clearly further work is required to
determine whether such aberrant EPCR expression
may induce cd T cell responses in epithelial tumours.
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